Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eloxatin Has 38% Share Of First-Line Colorectal Cancer Market, Sanofi Says

Executive Summary

Sanofi-Synthelabo's Eloxatin has taken a greater than one-third share of the first-line advanced colorectal cancer market from Camptosar ahead of FDA approval, Exec VP-Operations Hanspeter Spek said

You may also be interested in...



Sanofi Eloxatin first-line approval

Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1"The Pink Sheet" Sept. 8, 2003, p. 26)...

Sanofi Eloxatin first-line approval

Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1"The Pink Sheet" Sept. 8, 2003, p. 26)...

Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003

Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel